DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Pomaglumetad
Pomaglumetad
The G Protein-Coupled Glutamate Receptors As Novel Molecular Targets in Schizophrenia Treatment— a Narrative Review
Effects of N-Acetylcysteine on Brain Glutamate Levels and Resting Perfusion in Schizophrenia
(12) United States Patent (10) Patent No.: US 9,114,138 B2 Cid-Nunez Et Al
Treatment of Schizophrenia Course Director: Philip Janicak, M.D
Hippocampal Dysfunction in the Pathophysiology of Schizophrenia: a Selective Review and Hypothesis for Early Detection and Intervention
State-Dependent Dopamine System Regulation Using Current and Novel Antipsychotic Drug Mechanisms: Developmental Implications in a Schizophrenia Model
Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
Protective Effect of Pro-Cognitive Training During Adolescence on Neuronal Coordination Deficit in a Pharmacological Model of Schizophrenia
SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Action S
Pharmacological Treatment of Cognitive Deficits in Nondementing Mental Health Disorders Trevor W
(NMDA) Receptor Glutamate Synapse
Development and Characterization of Novel Allosteric Modulators Acting on Metabotropic Glutamate Receptors 2 and 3
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
Methamphetamine Addiction
The Role of G Protein-Coupled Receptors (Gpcrs) and Calcium Signaling in Schizophrenia
Management of Dementia-Related Psychosis, Agitation and Aggression
3 Mechanisms in Primate Dorsolateral Prefrontal Cortex: Evidence for Both Presynaptic and Postsynaptic Actions
Group II Metabotropic Glutamate Receptors As Targets for Novel Antipsychotic Drugs
Top View
Translating Advances in the Molecular Basis of Schizophrenia Into Novel Cognitive Treatment Strategies
2012 Annual Report Notice of 2013 Annual Meeting Proxy Statement Putting the Pieces Together the Lilly Promise Advancing Health
Clinical Trials in Psychiatry: Focusing on Antipsychotic Development
Mglur2/3 Agonist LY379268 Rescues NMDA and GABAA Receptor Level Deficits Induced in a Two-Hit Mouse Model of Schizophrenia
Specific Activation of Mglu2 Induced IGF-1R Transactivation in Vitro
PDF File of an Unedited Manuscript That Has Been Accepted for Publication
ET Fast Forward
Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention
King's Research Portal
Curriculum Vitae: Robert W. Baker
A Roadmap for Development of Novel Antipsychotic Agents Based on a Risperidone Scaffold
A Double-Blind, Placebo-Controlled Comparator Study of LY2140023
Pomaglumetad Methionil (Also Known As POMA, LY-2140023)
Mary-Anne Bellwood Mackay
Mglur3 Knockout Mice Show a Working Memory Defect and an Enhanced Response to MK-801 in the T- and Y-Maze Cognitive Tests
Update on New and Emerging Treatments for Schizophrenia
Metabotropic Glutamate Receptor 2 Activation: Computational Predictions and Experimental Validation
Proof of Mechanism and Target Engagement Of
Targeting Metabotropic Glutamate Receptors for Novel Treatments of Schizophrenia James Maksymetz1,2, Sean P
ITI-007 for the Treatment of Schizophrenia: a 4-Week Randomized, Double-Blind, Controlled Trial Jeffrey A
Clinical Efficacy and Target Engagement of Glutamatergic Drugs